Proteomics

Dataset Information

0

Proteomic analysis identifies novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy

ABSTRACT: Resistance to Human Epidermal Growth Factor Receptor (HER)-targeted cancer therapies appear to be occurring via common pathways, despite differences in their mechanism of action. This suggests that combination therapies targeting alternative pathways will be needed to overcome resistance. We have used a global proteomics approach to identify common signaling nodes that are required for driving HER2-independent resistance mechanisms to the pan-HER family kinase inhibitors AZD8931 and lapatinib. A novel set of epithelial–to-mesenchymal transition (EMT) associated proteins linked to resistance to pan-HER family targeted therapy was identified. We demonstrate that a sub-set of these genes are predictive of prognosis within the ERBB2 subtype of breast cancers and are worthy of further study in the context of preventing resistance to anti-HER family agents. Furthermore, targeting these pathways, perhaps via combination with galectin-1 or Axl inhibitors may provide additional strategies for the treatment of resistant tumours.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Thierry Le Bihan  

PROVIDER: MSV000080706 | MassIVE | Tue Mar 28 22:30:00 BST 2017

SECONDARY ACCESSION(S): PXD002057

REPOSITORIES: MassIVE

Json Xml

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1
altmetric image

Publications

Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapies in the treatment of HER2-positive breast cancer is a major clinical problem. To identify pathways linked to resistance, we generated HER2-positive breast cancer cell lines which are resistant to either lapatinib or AZD8931, two pan-HER family kinase inhibitors. Resistance was HER2 independent and was associated with epithelial-to-mesenchymal transition (EMT), resulting in increased proliferation and migration of the  ...[more]

Similar Datasets

Proteomics Proteomic analysis identifies novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy
2016-02-22 | PXD002057 | Pride
Transcriptomics Widespread multi-targeted therapy resistance via drug-induced secretome fucosylation
2023-04-05 | GSE160205 | GEO
Proteomics Widespread multi-targeted therapy resistance via drug-induced secretome fucosylation
2023-04-05 | PXD022240 | Pride
Transcriptomics Combined Inhibition of MNK Signaling and BET Proteins Reveals TGM2 as a Novel Vulnerability in Melanoma
2024-06-30 | GSE260507 | GEO
Transcriptomics Enhanced combination treatment on osteosarcoma by mitigating drug-induced oncogenic signaling pathway activation
2024-10-29 | GSE278302 | GEO
Proteomics Combined inhibition of MNK signaling and BET proteins reveals TGM2 as a novel vulnerability in melanoma
2024-10-01 | PXD044698 | Pride
Transcriptomics Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers
2017-08-01 | GSE99015 | GEO
Transcriptomics Combination therapy strategy to overcome resistance to EGFR inhibitors in NSCLC with Paeoniae Radix
2024-03-24 | GSE261880 | GEO
Transcriptomics Melanoma therapeutic strategies that select against resistance by exploiting MYC-driven evolutionary convergence
2017-11-16 | GSE99923 | GEO
Genomics Combinatorial treatment with PARP and MAPK inhibitors overcomes phenotype switch-driven drug resistance in advanced melanoma
2023-08-24 | GSE221241 | GEO